<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRP</journal-id><journal-title-group><journal-title>Asian Case Reports in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2328-045X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRP.2020.84007</article-id><article-id pub-id-type="publisher-id">ACRP-38801</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRP20200400000_65005451.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  2例儿童急性淋巴细胞白血病合并颅内静脉窦血栓形成并文献复习
  Two Children with Acute Lymphoblastic Leukemia Complicated with Intracranial Venous Sinus Thrombosis and Literature Review
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>琴华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>学东</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>南方医科大学南方医院，广东 广州</addr-line></aff><aff id="aff2"><addr-line>南方医科大学，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>26</day><month>11</month><year>2020</year></pub-date><volume>08</volume><issue>04</issue><fpage>33</fpage><lpage>39</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨分析急性淋巴细胞白血病患儿在诱导缓解化疗过程中并发颅内静脉窦血栓的相关危险因素及后续治疗。方法：回顾性分析南方医院2例急性淋巴细胞白血病患儿在VDLP诱导缓解化疗过程中并发颅内静脉窦血栓形成的临床表现及形成血栓的危险因素及相关治疗，并结合文献进行分析。结果：2例患儿在我院完善骨髓MICM，明确诊断为急性淋巴细胞白血病，予CCCG-ALL-2015方案开始VDLP诱导缓解化疗，诱导过程1例出现抽搐、小便失禁、意识不清，伴有凝血功能异常。1例反复出现头痛伴非喷射性呕吐，两例患儿进行头颅MRI支持颅内静脉窦血栓形成，给予抗凝治疗后病情好转，顺利进行后续巩固治疗。讨论：随着化疗方案不断优化，儿童ALL缓解率已可达90%以上，总体生存率已达80%以上。特别是近年来左旋门冬旋胺酶和培门冬酶的应用，进一步提高了急性淋巴细胞白血病化疗过程中的缓解率及无病生存率，但关注化疗带来益处的同时也应密切关注并发症的发生。其中血栓栓塞性疾病并未得到相应的关注。在小儿恶性肿瘤中，ALL是最易发生血栓的恶性肿瘤，不仅是急性淋巴细胞白血病疾病本身，特别是在VDLP诱导过程中泼尼松联合门冬酰胺酶诱导过程中最易发生。患儿在化疗过程中出现头痛、抽搐、呕吐等应及时完善头颅CT、头颅MRI。可及时发现病情，及早诊断，及时有效治疗可减少相关后遗症的发生。
   Objective: To investigate the risk factors and subsequent treatment of intracranial venous sinus thrombosis (CVT) in children with acute lymphoblastic leukemia (ALL) during induction remission chemotherapy. Methods: The clinical manifestations, risk factors and related treatments of intra-cranial venous sinus thrombosis during VDLP induced remission chemotherapy in 2 children with acute lymphoblastic leukemia in Nanfang Hospital were analyzed retrospectively, and the literature was combined for analysis. Results: The bone marrow MICM of 2 children was improved in our hos-pital and was clearly diagnosed as acute lymphoblastic leukemia. VDLP induced remission chemo-therapy was started with THE CCCG-ALL-2015 regimen. During the induction process, 1 child had convulsions, urinary incontinence, confusion, and abnormal coagulation function. One case had re-current headache with non-ejection vomiting, and two cases underwent cranial MRI to support in-tracranial venous sinus thrombosis. After anticoagulant treatment, the condition was improved, and subsequent consolidation treatment was carried out successfully. Discussion: With the contin-uous optimization of chemotherapy regimens, the remission rate of ALL in children has reached more than 90%, and the overall survival rate has reached more than 80%. Especially in recent years, the application of l-aspartase and peraspartase has further improved the remission rate and disease-free survival rate in the course of chemotherapy for acute lymphoblastic leukemia. However, it is necessary to pay close attention to the occurrence of complications while paying attention to the benefits of chemotherapy. Thromboembolic diseases have not received corresponding attention. Among malignant tumors in children, ALL is the most prone to thrombosis, not only in acute lym-phoblastic leukemia itself, but especially in the induction of prednisone combined with asparagi-nase during VDLP. In the course of chemotherapy, headache, convulsion, vomiting and other symp-toms, cranial CT and cranial MRI should be timely perfected. Timely detection of disease, early di-agnosis, timely and effective treatment can reduce the occurrence of related sequelae.
 
</p></abstract><kwd-group><kwd>急性淋巴细胞白血病，儿童，颅内静脉窦血栓形成, Acute Lymphoblastic Leukemia (ALL)</kwd><kwd> Children</kwd><kwd> Intracranial Venous Sinus Thrombosis (CVST)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨分析急性淋巴细胞白血病患儿在诱导缓解化疗过程中并发颅内静脉窦血栓的相关危险因素及后续治疗。方法：回顾性分析南方医院2例急性淋巴细胞白血病患儿在VDLP诱导缓解化疗过程中并发颅内静脉窦血栓形成的临床表现及形成血栓的危险因素及相关治疗，并结合文献进行分析。结果：2例患儿在我院完善骨髓MICM，明确诊断为急性淋巴细胞白血病，予CCCG-ALL-2015方案开始VDLP诱导缓解化疗，诱导过程1例出现抽搐、小便失禁、意识不清，伴有凝血功能异常。1例反复出现头痛伴非喷射性呕吐，两例患儿进行头颅MRI支持颅内静脉窦血栓形成，给予抗凝治疗后病情好转，顺利进行后续巩固治疗。讨论：随着化疗方案不断优化，儿童ALL缓解率已可达90%以上，总体生存率已达80%以上。特别是近年来左旋门冬旋胺酶和培门冬酶的应用，进一步提高了急性淋巴细胞白血病化疗过程中的缓解率及无病生存率，但关注化疗带来益处的同时也应密切关注并发症的发生。其中血栓栓塞性疾病并未得到相应的关注。在小儿恶性肿瘤中，ALL是最易发生血栓的恶性肿瘤，不仅是急性淋巴细胞白血病疾病本身，特别是在VDLP诱导过程中泼尼松联合门冬酰胺酶诱导过程中最易发生。患儿在化疗过程中出现头痛、抽搐、呕吐等应及时完善头颅CT、头颅MRI。可及时发现病情，及早诊断，及时有效治疗可减少相关后遗症的发生。</p></sec><sec id="s2"><title>关键词</title><p>急性淋巴细胞白血病，儿童，颅内静脉窦血栓形成</p></sec><sec id="s3"><title>Two Children with Acute Lymphoblastic Leukemia Complicated with Intracranial Venous Sinus Thrombosis and Literature Review<sup> </sup></title><p>Qinhua Zheng<sup>1</sup>, Xuedong Wu<sup>2</sup></p><p><sup>1</sup>Southern Medical University, Guangzhou Guangdong</p><p><sup>2</sup>Nanfang Hospital, Southern Medical University, Guangzhou Guangdong</p><p><img src="//html.hanspub.org/file/1-2460112x4_hanspub.png" /></p><p>Received: Nov. 3<sup>rd</sup>, 2020; accepted: Nov. 19<sup>th</sup>, 2020; published: Nov. 26<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/1-2460112x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the risk factors and subsequent treatment of intracranial venous sinus thrombosis (CVT) in children with acute lymphoblastic leukemia (ALL) during induction remission chemotherapy. Methods: The clinical manifestations, risk factors and related treatments of intracranial venous sinus thrombosis during VDLP induced remission chemotherapy in 2 children with acute lymphoblastic leukemia in Nanfang Hospital were analyzed retrospectively, and the literature was combined for analysis. Results: The bone marrow MICM of 2 children was improved in our hospital and was clearly diagnosed as acute lymphoblastic leukemia. VDLP induced remission chemotherapy was started with THE CCCG-ALL-2015 regimen. During the induction process, 1 child had convulsions, urinary incontinence, confusion, and abnormal coagulation function. One case had recurrent headache with non-ejection vomiting, and two cases underwent cranial MRI to support intracranial venous sinus thrombosis. After anticoagulant treatment, the condition was improved, and subsequent consolidation treatment was carried out successfully. Discussion: With the continuous optimization of chemotherapy regimens, the remission rate of ALL in children has reached more than 90%, and the overall survival rate has reached more than 80%. Especially in recent years, the application of l-aspartase and peraspartase has further improved the remission rate and disease-free survival rate in the course of chemotherapy for acute lymphoblastic leukemia. However, it is necessary to pay close attention to the occurrence of complications while paying attention to the benefits of chemotherapy. Thromboembolic diseases have not received corresponding attention. Among malignant tumors in children, ALL is the most prone to thrombosis, not only in acute lymphoblastic leukemia itself, but especially in the induction of prednisone combined with asparaginase during VDLP. In the course of chemotherapy, headache, convulsion, vomiting and other symptoms, cranial CT and cranial MRI should be timely perfected. Timely detection of disease, early diagnosis, timely and effective treatment can reduce the occurrence of related sequelae.</p><p>Keywords:Acute Lymphoblastic Leukemia (ALL), Children, Intracranial Venous Sinus Thrombosis (CVST)</p><disp-formula id="hanspub.38801-formula2"><graphic xlink:href="//html.hanspub.org/file/1-2460112x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2460112x7_hanspub.png" /> <img src="//html.hanspub.org/file/1-2460112x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性淋巴细胞白血病(Acute lymphoblastic leukemia, ALL)是儿童最常见最高发的恶性肿瘤，儿童年发病率为4/10万左右 [<xref ref-type="bibr" rid="hanspub.38801-ref1">1</xref>]，约占儿童恶性肿瘤的1/3 [<xref ref-type="bibr" rid="hanspub.38801-ref2">2</xref>]。由于治疗方法的不断进步及优化，目前ALL总体生存率已达80%以上。特别是20世纪70年代以来，左旋门冬旋胺酶(L-asparaginase, L-ASP)和近年来培门冬酶(PEG-ASP)的应用，进一步提高了急性淋巴细胞白血病化疗过程中的缓解率及无病生存率。可以说是儿童ALL化疗中具有里程碑意义的药物。尽管患儿能从中获益，但仍不能忽视患儿化疗过程中应用L-ASP中引起的不良反应：包括超敏反应、出凝血功能异常、门冬酰胺酶相关的急性胰腺炎、肝功能异常、暂时性高血糖等。这些不良反应甚至导致患儿后续化疗再也不能继续使用L-ASP或PEG-ASP，严重时可危及患儿生命 [<xref ref-type="bibr" rid="hanspub.38801-ref3">3</xref>]。本文报道我院2例ALL患儿在VDLP诱导缓解阶段中，发生颅内静脉窦血栓。后予抗凝治疗后症状均好转，顺利进入巩固治疗。</p></sec><sec id="s6"><title>2. 研究对象</title><p>例1：患儿，男，8岁，因“反复发热4月余，四肢关节肿痛半月余”入院，入院血常规示：WBC 4.69 &#215; 10<sup>9</sup>/T，NEU0.85 &#215; 10<sup>9</sup>/L PLT 18 &#215; 10<sup>9</sup>/L，HCT 0.251 L/L，HGB 98 g/L，NEU% 1.3%，肝肾功能/心肌酶，凝血四项、D-二聚体无明显异常。查体：面色苍白，咽充血，双侧颈部触及数个肿大淋巴结，肝脾肋下未触及。入院后完善骨髓MICM，明确诊断为急性淋巴细胞白血病(B细胞型)。</p><p>例2：患儿，男，13岁，因“发热5天”入院，白细胞计数WBC 5.88 &#215; 10<sup>9</sup>/L，中性粒细胞总数NEU 0.07 &#215; 10<sup>9</sup>/L，血红蛋白测定HGB 72 g/L，血小板计数PLT 117 &#215; 10<sup>9</sup>/L。凝血四项无明显异常，血浆D-二聚体测定D-Dimer 93.27 mg/L (参考值：0.00~0.55 mg/L) FEU，3P阴性；铁蛋白Ferr 1378.90 ng/ml。查体：面色苍白，咽充血，双侧颈部触及数个肿大淋巴结，肝脾肋下未触及。入院后完善骨髓MICM，明确诊断为急性淋巴细胞白血病(T细胞型)。</p></sec><sec id="s7"><title>3. 结果</title><p>例1：诊断明确，并排除化疗前相关禁忌后予CCCG-2015-ALL方案予VDLP诱导缓解化疗(D6予培门冬酶2000 U/m<sup>2</sup>肌注)，化疗D6患儿出现头痛伴非喷射性呕吐，头颅MRI示(表1：图1~7)：1) 右侧枕骨内板下短T1信号影，双侧枕骨内板下及左侧枕叶FLAIR稍高信号影，结合MRV及SWAN，考虑为窦汇及双侧横窦、左侧乙状窦静脉血栓形成可能性大，请结合临床；2) 左侧上颌窦及双侧筛窦炎症；3) 脑部A未见明显异常。考虑患儿颅内静脉窦血栓形成。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Case1prior treatment head MR</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x9_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref> 图1</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x10_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref> 图2</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x11_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig3">Figure 3</xref> 图3</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x12_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig4">Figure 4</xref> 图4</th></tr></thead><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x13_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig5">Figure 5</xref> 图5</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x14_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig6">Figure 6</xref> 图6</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x15_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig7">Figure 7</xref> 图7</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 例1治疗前头颅MRI</p><p>予速碧林、华法林抗凝、甘露醇降低颅内压等对症治疗，治疗11天后患儿头痛较前好转，后复查头颅MRI未见明显异常。后顺利进入巩固治疗，目前已结疗。复查后MRI见表2：图8~15。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Case 1 after treatment head MR</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x16_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig8">Figure 8</xref> 图8</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x17_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig9">Figure 9</xref> 图9</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x18_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>0 图10</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x19_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>1 图11</th></tr></thead><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x20_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>2 图12</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x21_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>3 图13</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x22_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>4 图14</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x23_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>5 图15</td></tr></tbody></table></table-wrap><p>表2. 例1治疗后头颅MRI</p><p>例2：诊断明确，并排除化疗前相关禁忌后予CCCG-2015-ALL方案予VDLP诱导缓解化疗(D6予培门冬酶2000 U/m<sup>2</sup>肌注)，化疗D17出现意识不清、呼之不应、双眼凝视、牙关紧闭，伴四肢抖动，小便失禁。完善凝血功能：纤维蛋白降解产物定量FDP-Y: 11.8 μg/mL，血浆D-二聚体测定D-Dimer 2.60 mg/L (参考范围：0.00~0.55 mg/L)；FEU，凝血四项：活化部分凝血活酶时间APTT35.7秒(参考范围22.7~31.8秒)，凝血酶时间测定TT20.0秒(参考范围：14.0~19.0秒)，血浆纤维蛋白原测定FbgC 0.66 g/L (参考范围：1.80~3.50 g/L)，TEG: K6.1 min。完善头颅MRI (表3：图16~23)：1) 石侧放射冠基底节–丘脑大脑脚、左侧丘脑、左侧大脑脚、双侧额项叶深部白质及左侧大脑半球皮层下多发长T2信号，考虑为脑梗塞可能性大；2) 大枕大池；3) 脑部MRA示：左侧优势型椎动脉；余颅内动脉未 见明显异常；4) 头颅MRV示：下矢状窦下段局部低信号影，左侧横窦、乙状窦、直窦走行区未见显影，考虑变异与血栓形成鉴别，请结合临床。</p><table-wrap-group id="3"><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Case 2 prior treatment head MR</title></caption><table-wrap id="3_1"><table><tbody><thead><tr><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x24_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>6 图16</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x25_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>7 图17</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x26_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>8 图18</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x27_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig1">Figure 1</xref>9 图19</th></tr></thead></tbody></table></table-wrap><table-wrap id="3_2"><table><tbody><thead><tr><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x28_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>0 图20</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x29_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>1 图21</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x30_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>2 图22</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x31_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>3 图23</th></tr></thead></tbody></table></table-wrap></table-wrap-group><p>表3. 例2治疗前头颅MRI</p><p>治疗上予甘露醇降颅压，肝素钠抗凝，补充纤维蛋白原，丙戊酸钠抗惊厥治疗，7天后患儿精神状态明显好转，继续按计划化疗，并复查头颅MRI (表4：图24~31)：1) 右侧放射冠–基底节–丘脑–大脑脚、双侧额顶叶深部白质异常信号影，范围较前缩小，右侧丘脑出血灶较前吸收；2) 大枕大池；3) 双侧下鼻甲肥大；4) 脑部MRA示：左侧优势型椎动脉；余脑动脉未见明显异常；5) 头颅MRV示：左侧横窦、乙状窦较前显影清楚，其内可见充盈缺损，考虑为血栓形成，较前好转。目前患儿恢复良好，已顺利进入CAT巩固阶段。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Case 2 after treatment head MR</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x32_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>4 图24</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x33_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>5 图25</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x34_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>6 图26</th><th align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x35_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>7 图27</th></tr></thead><tr><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x36_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>8 图28</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x37_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig2">Figure 2</xref>9 图29</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x38_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig3">Figure 3</xref>0 图30</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2460112x39_hanspub.png" xlink:type="simple"/></inline-formula> <xref ref-type="fig" rid="fig3">Figure 3</xref>1 图31</td></tr></tbody></table></table-wrap><p>表4. 例2治疗后头颅MRI</p></sec><sec id="s8"><title>4. 讨论</title><p>急性淋巴细胞白血病(ALL)是小儿最常见的恶性肿瘤，同时也是最容易合并血栓的恶性肿瘤，据有关报道患儿血栓形成的风险在1%到37%之间。Caruso V等 [<xref ref-type="bibr" rid="hanspub.38801-ref4">4</xref>] 研究分析的17项前瞻性研究的meta分析中，其中包括了1752名儿童，结合并分析所有已发表的关于小儿ALL与血栓形成之间关系的数据。17项前瞻性研究的1752名儿童血栓发生率为5.2% (95% CI: 4.2~6.4)。风险取决于几个因素：</p><p>1) 大多数的血栓事件发生在诱导缓解阶段的治疗，尤其是蒽环类药物和强的松、天门冬酰胺酶(ASP)，其中急性淋巴细胞白血病(ALL)儿童的血栓栓塞发生率在应用ASP、长春新碱和强的松治疗的过程中为2.4%到11.5% [<xref ref-type="bibr" rid="hanspub.38801-ref5">5</xref>]。血栓发生部位以中枢神经系统较为多见，其他还有四肢深静脉栓塞、肺栓塞、肾静脉栓塞、表皮静脉栓塞等 [<xref ref-type="bibr" rid="hanspub.38801-ref6">6</xref>]。而应用较低剂量的天门冬酰胺酶(ASP)与血栓形成的发生率最相关，ASP导致凝血障碍的机制主要是：ASP可使AT-III减少，这是凝血功能异常最主要的原因，另外还可减少α2巨球蛋白、蛋白C和S等抗凝因子，并导致血管内皮损伤、血小板活性增高，这些都参与了凝血障碍的发生 [<xref ref-type="bibr" rid="hanspub.38801-ref7">7</xref>]；</p><p>2) 嗜血栓性基因异常似乎也经常与血栓形成有关；</p><p>3) 所有儿童的血栓形成风险都是显著的，但新生儿及婴幼儿发病率最高，这可能与中心静脉的置入且这些患儿血管相对狭窄有关。此外，儿童进入青春期也是疾病高发期 [<xref ref-type="bibr" rid="hanspub.38801-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.38801-ref8">8</xref>]。</p><p>近年来随着对血栓栓塞性疾病的认识的不断提高，国内关于在ALL化疗过程中出现血栓的病例报道也越来越多，师晓东等 [<xref ref-type="bibr" rid="hanspub.38801-ref8">8</xref>] 回顾分析2007年~2012年我国国内报道的血栓栓塞性病例中，都集中发生在患儿VDLP诱导过程中，特别是青少年患儿在应用门冬酰胺酶后伴随发生出凝血功能异常，继而发生血栓栓塞性疾病。这也跟国际报道相关病例基本相符。另外T-ALL患者和在诱导过程中接受强的松治疗的患者发生静脉血栓栓塞的风险最高。在这类人群中，用地塞米松替代强的松可能有助于降低静脉血栓栓塞率，但需要进一步的研究 [<xref ref-type="bibr" rid="hanspub.38801-ref9">9</xref>]。</p><p>对于静脉栓塞的治疗宜早，抗凝治疗为首选，对于无抗凝禁忌症应尽早抗凝治疗，促进血栓溶解，推荐给予低分子肝素钠皮下注射 [<xref ref-type="bibr" rid="hanspub.38801-ref10">10</xref>]。但抗凝有时可发生出血性并发症，特别是脑出血可危及生命，有时可配合血浆制品支持治疗，如新鲜冷冻血浆，但有报道提示应注意其促凝风险。本例2患儿予抗凝治疗过程中就出现合并出血情况。因此，抗凝治疗过程中，应密切监测凝血功能，及时调整治疗方案 [<xref ref-type="bibr" rid="hanspub.38801-ref6">6</xref>]。</p><p>在ALL患儿开始VDLP诱导缓解阶段，尤其是应用ASP后应密切监测患儿的凝血功能，一旦出现头痛、呕吐、抽搐、意识障碍等神经系统症状，及时完善头颅MRV/CT静脉显影/DSA等影像学检查可明确诊断，并密切监测凝血功能等检查，及早的诊断，尽早的抗凝治疗可有效改善预后及严重并发症的发生。</p></sec><sec id="s9"><title>致谢</title><p>该病例报道已获得患方的知情同意，感谢患方的宝贵临床资料。</p></sec><sec id="s10"><title>文章引用</title><p>郑琴华,吴学东. 2例儿童急性淋巴细胞白血病合并颅内静脉窦血栓形成并文献复习Two Children with Acute Lymphoblastic Leukemia Complicated with Intracranial Venous Sinus Thrombosis and Literature Review[J]. 亚洲儿科病例研究, 2020, 08(04): 33-39. https://doi.org/10.12677/ACRP.2020.84007</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38801-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hunger, S.P. and Mullighan, C.G. (2015) Acute Lymphoblastic Leukemia in Children. The New England Journal of Medicine, 373, 1541-1552. &lt;br&gt;https://doi.org/10.1056/NEJMra1400972</mixed-citation></ref><ref id="hanspub.38801-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Inaba, H., Greaves, M. and Mullighan, C.G. (2013) Acute Lymphoblastic Leukaemia. The Lancet, 381, 1943-1955.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(12)62187-4</mixed-citation></ref><ref id="hanspub.38801-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">李硕, 卢新天, 华瑛, 等. 儿童急性淋巴细胞白血病应用门冬酰胺酶治疗的临床研究[J]. 中国小儿血液与肿瘤杂志, 2017, 22(1): 24-30.</mixed-citation></ref><ref id="hanspub.38801-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Caruso, V., Iacoviello, L., Di Castelnuovo, A., et al. (2006) Thrombotic Complications in Childhood Acute Lymphoblastic Leukemia: A Me-ta-Analysis of 17 Prospective Studies Comprising 1752 Pediatric Patients. Blood, 108, 2216-2222. &lt;br&gt;https://doi.org/10.1182/blood-2006-04-015511</mixed-citation></ref><ref id="hanspub.38801-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Nowak-Göttl, U., Wermes, C., Junker, R., et al. (1999) Pro-spective Evaluation of the Thrombotic Risk in Children with Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors. Blood, 93, 1595-1599. &lt;br&gt;https://doi.org/10.1182/blood.V93.5.1595</mixed-citation></ref><ref id="hanspub.38801-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">何海龙, 范俊杰, 赵文理, 等. 急性淋巴细胞白血病应用门冬酰胺酶致静脉栓塞3例[J]. 实用儿科临床杂志, 2007, 22(23): 1791-1836.</mixed-citation></ref><ref id="hanspub.38801-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mitchell, L., Hoogendoorn, H., Giles, A.R., et al. (1994) Increased Endogenous Thrombin Generation in Children with Acute Lymphoblastic Leukemia: Risk of Thrombotic Complications in L’Asparaginase-Induced Antithrombin III Deficiency. Blood, 83, 386-391. &lt;br&gt;https://doi.org/10.1182/blood.V83.2.386.386</mixed-citation></ref><ref id="hanspub.38801-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">师晓东, 李娟娟, 刘嵘, 等. 加强对小儿血液系统恶性肿瘤合并血栓栓塞性疾病的认识[J]. 中国医刊, 2014, 49(1): 15-18.</mixed-citation></ref><ref id="hanspub.38801-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Freyer, C.W., Carulli, A., Ganetsky, A., et al. (2020) Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation. Leuk Lymphoma, 61, 2200-2207.  
&lt;br&gt;https://doi.org/10.1080/10428194.2020.1765239</mixed-citation></ref><ref id="hanspub.38801-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">高丹丹, 袁冠前, 谭俊, 等. 颅内静脉系统血栓形成17例临床分析[J]. 临床军医杂志, 2017, 45(12): 1222-1225.</mixed-citation></ref></ref-list></back></article>